インタビュー
Poster Discussion Session：「転移性肺癌」の共同座長Shirish M. Gadgeel氏に聞く
学会3日目の正午から行われたPoster Discussion Session「転移性肺癌」では，当日の午前中に発表されたポスター・肺癌演題24題が討議の対象となった。特に個別化治療や新規薬剤に関する演題が目を引いたが，このセッションの共同座長を務めたShirish M. Gadgeel氏（ウェイン州立大学カルマノス癌研究所）は，本インタビューのなかで，個別化治療を担う新規薬剤への強い期待感とともに，日本の研究者の世界的貢献について語ってくれた。（平井佐知）
| 編集部 | 今年のASCOの肺癌演題について，どのような印象をもたれましたか。 |
| Gadgeel氏 |  |
Get the Flash Player to see this player.
|
Download（クリックで保存） |
lung cancer：肺癌
tumors：腫瘍
restart：再始動させる
This year’s ASCO has been exciting for lung cancer, primarily because we recognize that if we are smart and identifying specific target and developing our drug for the target and identifying the patients of whose tumors have the target, that we can be very successful, definitely much better than what we were before. It is also I feel promising or exciting because we do realize that if we are not smart we feel miserably. So I think that it is exciting because I think it is going to make us think much harder, learn much better, when restart next trials.
| 編集部 | 肺癌治療の今後の方向性についてのお考えをお聞かせください。 |
| Gadgeel氏 | |
Get the Flash Player to see this player.
|
Download（クリックで保存） |
subset：サブセット
non-small cell：非小細胞
small cell lung cancer：小細胞肺癌
molecular：分子の
The trend of lung cancer really is towards identifying small subsets of lung cancer. That is definitely happened in non-small cell, not yet happened in small cell lung cancer. And truly it is going to be trying to recognize what does the basic molecular change within the tumor and trying to focus on that aspect to develop the drugs. There are lots of promising drugs. But I think just using it randomly is not going to take us anywhere.
| 編集部 | 日本の研究者の肺癌治療への貢献についてはどのようにお考えですか。 |
| Gadgeel氏 | |
Get the Flash Player to see this player.
|
Download（クリックで保存） |
ALK：未分化リンパ腫キナーゼ(anaplastic lymphoma kinase)
translocation：転座
germ：（発展の基礎となる）兆し
complement：補足する
emerge：明らかになる
relevant：関連のある
tolerability：耐容性
toxicity：毒性
vice versa：逆に
I actually think Japanese oncologists have done some of the best work. So, as you know the ALK translocation was identified by Japanese investigators. Their paper in Nature was what led to this identification. I really feel that the work (which has) been germ in Japan, all for that matter in East Asia really is very important because it really complements the work that has been done in the western part of the world because the data emerging is relevant for the populations there. But also helps understand the disease in both parts of the world. So I think overall, the work done by Japanese individuals is very very important. I think the tolerability and the toxicity is different in Japan. To some extent than what we see in US. And I think the knowledge gained in Japan is going to help in US vice versa.
